Short answer
BioAge Labs, Inc. (BIOA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $298,000 (down 85.5% year over year) with net income of −$34M.
Q3 2026 key financials · XBRL
- Revenue
- $298,000
- −85.5% YoY · −87.8% QoQ
- Net income
- −$34M
- −66.1% YoY · −28.4% QoQ
- Operating margin
- -12554.0%
- EPS (diluted)
- −$0.73
- −30.4% YoY · −23.7% QoQ
Source: XBRL data from the BioAge Labs, Inc. (BIOA) Q3 2026 10-Q on SEC EDGAR. USD.
BioAge Labs, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $0.3M, down 85% YoY from $2.1M, reflecting a $1.7M Novartis catch-up adjustment
- Net loss $33.5M vs $20.2M YoY, with operating expenses $37.7M vs $25.2M
- BGE-102 R&D spending $17.8M vs $4.7M, the strongest program; other programs $4.4M vs $7.7M
- Cash, equivalents and marketable securities $352.3M; operating cash used $74.3M through nine months
- Funding expected through 2029; QUELL-CV topline data anticipated fourth quarter 2026, with additional capital needs and clinical risks remaining
Risk Factors
- Newly added regulatory risk: BIOSECURE Act, triggered by WuXi AppTec’s June 8, 2026 designation on the 1260H List
- Most material update: QUELL-DME began dosing approximately 180 participants, including combination therapy with anti-VEGF
- Near-term clinical risk: QUELL-CV topline data anticipated in fourth quarter of 2026, with hsCRP reduction potentially not translating into cardiovascular benefit
- Financial risk: $352.3 million in cash, equivalents and marketable securities expected to fund operations through 2029
- Manufacturing risk: China and India suppliers exposed to tariffs, trade restrictions and supply-chain disruption
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BioAge Labs, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.